Medovent GmbH

Mainz, Germany

Medovent GmbH

Mainz, Germany
SEARCH FILTERS
Time filter
Source Type

Patent
Medovent GmbH | Date: 2017-01-18

A water-soluble solid or water-soluble gel-like tissue dressing material for use in a method of treating a tissue of a patient, the method comprising the steps of: applying the water-soluble solid or water soluble gel-like tissue dressing material in contact with the patients tissue; and allowing the water-soluble tissue dressing material to convert into a form in which it is insoluble in water at neutral pH.


Gonzalez-Perez F.,Autonomous University of Barcelona | Ale A.,Autonomous University of Barcelona | Santos D.,Autonomous University of Barcelona | Barwig C.,Medovent GmbH | And 3 more authors.
European Journal of Neuroscience | Year: 2016

After peripheral nerve injuries, damaged axons can regenerate but functional recovery is limited by the specific reinnervation of targets. In this study we evaluated if motor and sensory neurites have a substrate preference for laminin and fibronectin in postnatal and adult stages. In postnatal dorsal root ganglia (DRG) explants, sensory neurons extended longer neurites on collagen matrices enriched with laminin (~50%) or fibronectin (~35%), whereas motoneurons extended longer neurites (~100%) in organotypic spinal cord slices embedded in fibronectin-enriched matrix. An increased percentage of parvalbumin-positive neurites (presumptive proprioceptive) vs. neurofilament-positive neurites was also found in DRG in fibronectin-enriched matrix. To test if the different preference of neurons for extracellular matrix components was maintained in vivo, these matrices were used to fill a chitosan guide to repair a 6-mm gap in the sciatic nerve of adult rats. However, the number of regenerating motor and sensory neurons after 1 month was similar between groups. Moreover, none of the retrotraced sensory neurons in DRG was positive for parvalbumin, suggesting that presumptive proprioceptive neurons had poor regenerative capabilities compared with other peripheral neurons. Using real-time PCR we evaluated the expression of α5β1 (receptor for fibronectin) and α7β1 integrin (receptor for laminin) in spinal cord and DRG 2 days after injury. Postnatal animals showed a higher increase of α5β1 integrin, whereas both integrins were similarly expressed in adult neurons. Therefore, we conclude that motor and sensory axons have a different substrate preference at early postnatal stages but this difference is lost in the adult. © 2016 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.4-2 | Award Amount: 7.76M | Year: 2011

The BIOHYBRID consortium was build up with the overall aim to develop, in a preclinical perspective, an innovative biohybrid artificial nerve device for the regenerative treatment of traumatic injuries of peripheral nerves. This consortium consists of three active and well integrated SMEs as well as seven academic partners that are recognised leaders in the scientific areas of interest for this project. Furthermore, another partner has substantiated expertises to meet the regulatory work for ATMP development. Traumatic injuries of peripheral nerves represent a major cause for morbidity and morbility in Europe and their social impact is considerably high. It has been estimated that the incidence of peripheral nerve injuries derived from trauma is about 300,000 cases per year. Moreover, nerve injuries are an important component of traumatic limb amputations, with an incidence of 2/100,000 persons per year described for hand amputations. Therefore, repair and regeneration of peripheral nerve injuries represent a major field where clinical application of innovative therapies in regenerative medicine should be sought. Peripheral nerve fibers are able to regenerate and lead to functional recovery provided that an appropriate milieu and guide is available. However, the clinical outcome of neural repair after extended substance loss after nerve injury is often unsatisfactory and therefore innovative strategies for improving the outcome after neural damage are in demand. The main objective of the BIOHYBRID project is the development of a regenerative therapy using an innovative biohybrid artificial nerve device with the goal of repairing damaged nerve trunks. The work program includes an integrated experimental approach bringing together the main aspects of regenerative medicine: a) reconstructive microsurgery, b) regenerative scaffolds and c) transplantation. This approach will allow the biological pre-fabrication of biohybrid nerve devices, their transplantation into nerve gaps in various animal models and the comprehensive evaluation of the regenerative outcome. The SME involvement, for the first time in this biomedical field, will not be limited to production and supply of materials and services but includes also active participation in the conduction of the experiments for in vivo preclinical assessment and follow-up. Based on the extensive basic and clinical experience within this consortium a biohybrid artificial nerve device will be developed together with standardised application and evaluation parameters. A key objective of this study will be to generate, for the first time, a protocol that can serve as a template for future clinical trials in the regenerative therapy of damaged peripheral nerves. The BIOHYBRID project with its consortium partners combines excellent expertise to successfully reach the objectives and stands therfore on the front line of regenerative medicine approaches.


Asia Pacific (APAC) Nerve Regeneration and Repair Market New Report by Data Bridge Market Research Asia-Pacific Nerve Regeneration and Repair Market, By Type (Biomaterials (Nerve Conduits, Nerve Protectors, Nerve Wraps, Nerve Connectors), Neurostimalation (Internal (SCS, DBS, VNS, SNS, GES), External (TENS, TMS, RES))), By Indication (Failed Back Surgery Syndrome, Parkinson’s disease, Urinary Incontinence, Epilepsy, Gastroparesis, Nerve Repair (Epineural, Perineural, Group Fascicular Repair), Grafting (Autograft, Allograft, Xenograft)), By End-User, By Country– Trends and Forecast to 2022 Dallas, TX, November 18, 2016 --( The APAC nerve regeneration and repair market is segmented based on product type, indication, end-user and geography. Request for sample pages: http://databridgemarketresearch.com/reports/asia-pacific-nerve-repair-and-regeneration-market/ The market segmented based on the product type, into 2 type’s biomaterial and neurostimulation segments. The neurostimulation segment is further classified into internal and external neurostimulation devices. Internal neurostimulation devices is further segmented into spinal cord stimulator (SCS), deep brain stimulator (DBS), vagus nerve stimulator (VNS), sacral nerve stimulator (SNS) and gastric nerve stimulator (GNS). External neurostimulation devices market is further segmented into transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS) and respiratory electrical stimulation (RES). On the basis of indications the market is segmented into failed back surgery syndrome, conditional regional pain syndrome, eschemia, Parkinson’s disease, Alzheimer’s, urinary incontinence, faecal incontinenece, epilepsy, gastroparesis, nerve repair, nerve grafting and others. Nerve repair segment is further segmented based on repair type into epineural repair, perineural repair and group fascicular repair. Nerve grafting segment is also further segmented based on graft types into autograft, allograft and xenograft. Based on end-users the market is segmented into Hospitals, Neurology Clinics, Home Healthcare, Community Healthcare. The major geographies covered in the reports scope are China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Taiwan, Indonesia, Australia and rest of APAC. The report of this market is further segmented into the countries like India, Japan, South Korea, Australia, Thailand and Taiwan. Read more: http://databridgemarketresearch.com/reports/asia-pacific-nerve-repair-and-regeneration-market/ The major players operating in this market are Medtronic, AxoGen Inc., Boston Scientific Corporation, Medovent GmbH, Baxter International, Checkpoint Surgical Inc., St. Jude Medical, Inc., Integra Lifesciences Corporation, Toyobo Co., Ltd., Nevro Corporation, Orthomed S.A.S., Collagen Matrix, Inc., Cyberonics, Inc., Polyganics B.V. and Stryker Corporation among other companies. About Data Bridge Market Research: Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Dallas, TX, November 18, 2016 --( PR.com )-- The market for nerve regeneration and repair has accounted to USD 960 million in 2015, growing at 14.1% during the forecast years to 2022.The APAC nerve regeneration and repair market is segmented based on product type, indication, end-user and geography.Request for sample pages: http://databridgemarketresearch.com/reports/asia-pacific-nerve-repair-and-regeneration-market/The market segmented based on the product type, into 2 type’s biomaterial and neurostimulation segments. The neurostimulation segment is further classified into internal and external neurostimulation devices. Internal neurostimulation devices is further segmented into spinal cord stimulator (SCS), deep brain stimulator (DBS), vagus nerve stimulator (VNS), sacral nerve stimulator (SNS) and gastric nerve stimulator (GNS). External neurostimulation devices market is further segmented into transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS) and respiratory electrical stimulation (RES).On the basis of indications the market is segmented into failed back surgery syndrome, conditional regional pain syndrome, eschemia, Parkinson’s disease, Alzheimer’s, urinary incontinence, faecal incontinenece, epilepsy, gastroparesis, nerve repair, nerve grafting and others. Nerve repair segment is further segmented based on repair type into epineural repair, perineural repair and group fascicular repair. Nerve grafting segment is also further segmented based on graft types into autograft, allograft and xenograft.Based on end-users the market is segmented into Hospitals, Neurology Clinics, Home Healthcare, Community Healthcare.The major geographies covered in the reports scope are China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Taiwan, Indonesia, Australia and rest of APAC. The report of this market is further segmented into the countries like India, Japan, South Korea, Australia, Thailand and Taiwan.Read more: http://databridgemarketresearch.com/reports/asia-pacific-nerve-repair-and-regeneration-market/The major players operating in this market are Medtronic, AxoGen Inc., Boston Scientific Corporation, Medovent GmbH, Baxter International, Checkpoint Surgical Inc., St. Jude Medical, Inc., Integra Lifesciences Corporation, Toyobo Co., Ltd., Nevro Corporation, Orthomed S.A.S., Collagen Matrix, Inc., Cyberonics, Inc., Polyganics B.V. and Stryker Corporation among other companies.About Data Bridge Market Research:Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Click here to view the list of recent Press Releases from Data Bridge Market Research


Gonzalez-Perez F.,Autonomous University of Barcelona | Cobianchi S.,Autonomous University of Barcelona | Geuna S.,University of Turin | Barwig C.,Medovent GmbH | And 3 more authors.
Microsurgery | Year: 2015

Biosynthetic guides can be an alternative to nerve grafts for reconstructing severely injured peripheral nerves. The aim of this study was to evaluate the regenerative capability of chitosan tubes to bridge critical nerve gaps (15 mm long) in the rat sciatic nerve compared with silicone (SIL) tubes and nerve autografts (AGs). A total of 28 Wistar Hannover rats were randomly distributed into four groups (n = 7 each), in which the nerve was repaired by SIL tube, chitosan guides of low (∼2%, DAI) and medium (∼5%, DAII) degree of acetylation, and AG. Electrophysiological and algesimetry tests were performed serially along 4 months follow-up, and histomorphometric analysis was performed at the end of the study. Both groups with chitosan tubes showed similar degree of functional recovery, and similar number of myelinated nerve fibers at mid tube after 4 months of implantation. The results with chitosan tubes were significantly better compared to SIL tubes (P < 0.01), but lower than with AG (P < 0.01). In contrast to AG, in which all the rats had effective regeneration and target reinnervation, chitosan tubes from DAI and DAII achieved 43 and 57% success, respectively, whereas regeneration failed in all the animals repaired with SIL tubes. This study suggests that chitosan guides are promising conduits to construct artificial nerve grafts. © 2014 Wiley Periodicals, Inc. Microsurgery 35:300-308, 2015. © 2014 Wiley Periodicals, Inc.


Gnavi S.,University of Turin | Barwig C.,Medovent GmbH | Freier T.,Medovent GmbH | Haastert-Talini K.,Hannover Medical School | And 2 more authors.
International Review of Neurobiology | Year: 2013

Various biomaterials have been proposed to build up scaffolds for promoting neural repair. Among them, chitosan, a derivative of chitin, has been raising more and more interest among basic and clinical scientists. A number of studies with neuronal and glial cell cultures have shown that this biomaterial has biomimetic properties, which make it a good candidate for developing innovative devices for neural repair. Yet, in vivo experimental studies have shown that chitosan can be successfully used to create scaffolds that promote regeneration both in the central and in the peripheral nervous system. In this review, the relevant literature on the use of chitosan in the nervous tissue, either alone or in combination with other components, is overviewed. Altogether, the promising in vitro and in vivo experimental results make it possible to foresee that time for clinical trials with chitosan-based nerve regeneration-promoting devices is approaching quickly. © 2013 Elsevier Inc.


Patent
Medovent GmbH | Date: 2010-02-02

A fluid-swellable fiber in particular for the use as a surgical suture, the fiber comprising chitosan, the fibers swelling ratio being less than 100%, and a fabric comprising the fiber. Moreover, a method of manufacturing from a chitosan-containing solution a fiber comprising chitosan, wherein during manufacture, the solution is brought into contact with a coagulation medium containing at least one organic solvent, a method of removing a fiber from a living organism, wherein the fiber is at least partly dissolved in a solvent applied from the outside, and a kit comprising a chitosan containing fiber and a solvent for at least partly dissolving the fiber.


A chitosan for use in an antimicrobial treatment of a patients tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patients tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patients tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition.


Patent
Medovent GmbH | Date: 2016-06-10

A kit comprising a tissue dressing material for being applied in contact with the tissue of a patient and a detachment solvent for removing the tissue dressing material from the tissue. A method of treating a tissue of a patient, the method comprising the steps of: applying a water-soluble tissue dressing material in contact with the patients tissue; and applying an acidic detachment solvent to the tissue dressing material for removing the tissue dressing material from the tissue. A method of treating a tissue of a patient, the method comprising the steps of: applying a liquid tissue dressing material in contact with the patients tissue; and applying a detachment solvent to the tissue dressing material for removing the tissue dressing material from the tissue. A method of treating a tissue of a patient, the method comprising the steps of: applying a water-soluble tissue dressing material in contact with the patients tissue; and allowing the water-soluble tissue dressing material to convert into a form in which it is insoluble in water at neutral pH. And a solid material comprising a polymer salt and glycerol, the glycerol content being at least 10% of the polymer salt content by weight, for use in a method of treating a human or animal tissue.


PubMed | Autonomous University of Barcelona and Medovent GmbH
Type: Journal Article | Journal: The European journal of neuroscience | Year: 2016

After peripheral nerve injuries, damaged axons can regenerate but functional recovery is limited by the specific reinnervation of targets. In this study we evaluated if motor and sensory neurites have a substrate preference for laminin and fibronectin in postnatal and adult stages. In postnatal dorsal root ganglia (DRG) explants, sensory neurons extended longer neurites on collagen matrices enriched with laminin (~50%) or fibronectin (~35%), whereas motoneurons extended longer neurites (~100%) in organotypic spinal cord slices embedded in fibronectin-enriched matrix. An increased percentage of parvalbumin-positive neurites (presumptive proprioceptive) vs. neurofilament-positive neurites was also found in DRG in fibronectin-enriched matrix. To test if the different preference of neurons for extracellular matrix components was maintained in vivo, these matrices were used to fill a chitosan guide to repair a 6-mm gap in the sciatic nerve of adult rats. However, the number of regenerating motor and sensory neurons after 1 month was similar between groups. Moreover, none of the retrotraced sensory neurons in DRG was positive for parvalbumin, suggesting that presumptive proprioceptive neurons had poor regenerative capabilities compared with other peripheral neurons. Using real-time PCR we evaluated the expression of 51 (receptor for fibronectin) and 71 integrin (receptor for laminin) in spinal cord and DRG 2 days after injury. Postnatal animals showed a higher increase of 51 integrin, whereas both integrins were similarly expressed in adult neurons. Therefore, we conclude that motor and sensory axons have a different substrate preference at early postnatal stages but this difference is lost in the adult.

Loading Medovent GmbH collaborators
Loading Medovent GmbH collaborators